Skip to content
Compass Pathways logo — We are unlocking pathways to be.

Compass Pathways

We are unlocking pathways to be.

Founded 2016 United Kingdom London, United Kingdom 305 employees IPO Total: $720.50M

General Information

Company Name Compass Pathways
Founded Year 2016
Location United Kingdom London, United Kingdom
Founders / Decision Makers
Team member
Employees 305
Funding Stage IPO
Business Model B2B, B2C, B2D
Revenue Model Product Sales, Service Fee, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Compass Pathways. To contact Compass Pathways, visit compasspathways.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Compass Pathways compare?

A PDF of Compass Pathways and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Compass Pathways soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Compass Pathways

Compass Pathways, founded in 2016, is a United Kingdom-based biotechnology firm on a mission to foster mental well-being. Their slogan, "Our vision is a world of mental wellbeing," encapsulates their commitment to revolutionizing mental health care.

Specializing in Biotechnology, Health Care, Health and Wellness, and Life Sciences, Compass Pathways is at the forefront of innovative treatment methodologies. The company is notably focused on their first clinical development program, the investigational COMP360 psilocybin treatment designed for individuals suffering from treatment-resistant depression.

In a strategic funding round on 16 August 2023, they secured a significant $125.00M Post-IPO Equity investment. This financial injection was led by a consortium of reputable investors including RA Capital Management, Vivo Capital, Laurion Capital, and Logos Capital, among others, underscoring investor confidence in their pioneering approach to mental health solutions.

Business keywords: mental health care, treatment-resistant depression, psilocybin therapy, clinical trials, psilocybin research, therapeutic innovation, evidence-based treatment, psychedelic compounds, mental wellbeing, patient access, depression treatment, psilocybin-assisted therapy, mental health innovation, unmet medical needs

Services & Products

psilocybin treatment research
mental health therapy development
therapist training programs
clinical trials
digital health platforms

Target Customers

patients with treatment-resistant depression patients with PTSD patients with anorexia nervosa mental health professionals medical researchers

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Debt $50.00M 1
Hercules Capital
01 Jan 2026
Post-IPO Equity $150.00M -
01 Jan 2025
Post-IPO Debt $285.00M 11
RA Capital Management, Vivo Capital +9
01 Aug 2023
IPO $127.50M -
01 Sep 2020
Series B $80.00M 8
Founders Fund, Able Partners +6
01 Apr 2020
Convertible Note Undisclosed 1
WPSS.bio
01 Sep 2019
Series A $25.00M 3
XYence Capital SGR, Mike Novogratz +1
01 Oct 2018
Seed £3.00M -
01 Aug 2017

Compass Pathways Alternatives & Competitors

View All Alternatives
Compass Pathways vs

Trailblazing a path to global mental health through psilocybin therapy

Seed
8 employees
Biotechnology, Health and Wellness
Compass Pathways vs

Gilgamesh is a clinical-stage biotech whose vision is to reshape how mental illnesses are treated by...

Grant
33 employees
Biotechnology, Health Care
Compass Pathways vs

The company was formed to identify, develop and commercialize psychotropic drugs with significant ma...

8 employees
Health Care, Pharmaceutical

FAQ About Compass Pathways

We are unlocking pathways to be.
Compass Pathways was founded in 2016.
Compass Pathways is headquartered in London, United Kingdom.
Compass Pathways has a B2B, B2C and B2D business model. Its revenue comes from Product Sales, Service Fee and Licensing.
Compass Pathways has approximately 305 employees.
Compass Pathways has completed 8 funding rounds, raising a total of $720.50M. The latest funding stage is IPO.
Compass Pathways offers: psilocybin treatment research, mental health therapy development, therapist training programs, clinical trials, digital health platforms.
Top alternatives and competitors to Compass Pathways include Clairvoyant Therapeutics, Gilgamesh Pharmaceuticals, Fabre-Kramer Pharmaceuticals, Inc., Aware Recovery Care, Inc., Joon. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Compass Pathways and Clairvoyant Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Compass Pathways, https://bouncewatch.com/company/compass-pathways, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout